Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease

Written By Matthew Blind
Matthew Blind
Previous

Swiftly and Circle K Launch Nation’s Largest Convenience Retail Alcohol Cashback Program, Opening a New Path to Digital Growth
Next

Kindbody Names David Stern as Chief Executive Officer to Lead Next Stage of Growth